Scilex Holding Company WT (SCLXW)

$0.27 -0.01 (-3.57%)
Market Cap N/A
Revenue (ttm) 46.74M
Net Income (ttm) -114.33M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 2,000
Avg Vol 13,580
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 78%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura...

Phone: 650 516 4310
Address:
960 San Antonio Road, Palo Alto, United States
Latest News on SCLXW
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026

Jun 16, 2026, 7:45 AM EDT - 7 days ago

Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026

SCLX

Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities

Jun 12, 2026, 7:45 AM EDT - 11 days ago

Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities

SCLX

Scilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities

Jun 4, 2026, 9:00 AM EDT - 19 days ago

Scilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities

SCLX

Scilex Holding Company Registration statement: Registration filing

Jun 2, 2026, 8:00 AM EDT - 21 days ago

Scilex Holding Company Registration statement: Registration filing

Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026

May 22, 2026, 1:15 PM EDT - 4 weeks ago

Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026

SCLX

Scilex Holding Company Quarterly report: Q1 2026

May 20, 2026, 8:00 AM EDT - 4 weeks ago

Scilex Holding Company Quarterly report: Q1 2026

Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited

May 5, 2026, 1:00 PM EDT - 7 weeks ago

Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited

SCLX

Scilex Holding Company Proxy statement: Proxy filing

May 5, 2026, 8:00 AM EDT - 7 weeks ago

Scilex Holding Company Proxy statement: Proxy filing

Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026

May 4, 2026, 6:00 AM EDT - 7 weeks ago

Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026

SCLX

Scilex Holding Company Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Scilex Holding Company Proxy statement: Proxy filing

Datavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum Platform

Apr 27, 2026, 5:40 PM EDT - 2 months ago

Datavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum Platform

DVLT SCLX

Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026

Apr 20, 2026, 9:00 AM EDT - 2 months ago

Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026

SCLX

Scilex Holding Company Registration statement: Registration filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Scilex Holding Company Registration statement: Registration filing

Scilex Holding Company Annual report: Q4 2025

Apr 10, 2026, 8:00 AM EDT - 2 months ago

Scilex Holding Company Annual report: Q4 2025

Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 2026

Feb 5, 2026, 6:00 AM EST - 4 months ago

Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 2026

DVLT SCLX

Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets

Jan 30, 2026, 9:00 AM EST - 5 months ago

Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets

SCLX

Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

Jan 2, 2026, 9:00 AM EST - 6 months ago

Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

SCLX

Scilex Holding Company Confirms Dream Bowl 2026 Meme Coin Claim Process on December 24, 2025 Drop by Datavault AI Inc.

Dec 23, 2025, 9:00 AM EST - 6 months ago

Scilex Holding Company Confirms Dream Bowl 2026 Meme Coin Claim Process on December 24, 2025 Drop by Datavault AI Inc.

SCLX

Scilex Holding Company Registration statement: Registration filing

Dec 16, 2025, 7:00 AM EST - 6 months ago

Scilex Holding Company Registration statement: Registration filing

Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.

Nov 26, 2025, 6:00 AM EST - 7 months ago

Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.

SCLX

Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds

Nov 25, 2025, 2:37 PM EST - 7 months ago

Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds

SCLX

Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds

Nov 24, 2025, 6:00 AM EST - 7 months ago

Scilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds

SCLX

Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.

Nov 21, 2025, 3:59 PM EST - 7 months ago

Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.

SCLX

Scilex Holding Company Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 7 months ago

Scilex Holding Company Quarterly report: Q3 2025

Scilex Holding Company Announces that the Board of Directors of Datavault AI Inc. Has Approved the Distribution of a Dream Bowl 2026 Meme Coin to All Eligible Scilex and Datavault AI Stockholders of Record and Set a Record Date of November 25, 2025

Nov 11, 2025, 9:30 AM EST - 8 months ago

Scilex Holding Company Announces that the Board of Directors of Datavault AI Inc. Has Approved the Distribution of a Dream Bowl 2026 Meme Coin to All Eligible Scilex and Datavault AI Stockholders of Record and Set a Record Date of November 25, 2025

SCLX

Scilex Holding Company Proxy statement: Proxy filing

Nov 7, 2025, 7:00 AM EST - 8 months ago

Scilex Holding Company Proxy statement: Proxy filing

Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real-World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from Datavault AI

Nov 4, 2025, 6:00 AM EST - 8 months ago

Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real-World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from Datavault AI

SCLX

Scilex Holding Company Announces the Sponsorship of Dream Bowl 2026 and Set a Record Date of November 14, 2025 for Its Shareholders to Receive Dream Bowl 2026 Meme Coin Distributed by DataVault AI

Nov 3, 2025, 9:53 AM EST - 8 months ago

Scilex Holding Company Announces the Sponsorship of Dream Bowl 2026 and Set a Record Date of November 14, 2025 for Its Shareholders to Receive Dream Bowl 2026 Meme Coin Distributed by DataVault AI

SCLX

Datavault AI Announces Record Date of Nov. 14, 2025, for Dream Bowl Draft Meme Coin Distribution to All Eligible Scilex and Datavault AI Shareholders

Nov 3, 2025, 8:45 AM EST - 8 months ago

Datavault AI Announces Record Date of Nov. 14, 2025, for Dream Bowl Draft Meme Coin Distribution to All Eligible Scilex and Datavault AI Shareholders

DVLT SCLX

Scilex Holding Company Proxy statement: Proxy filing

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Scilex Holding Company Proxy statement: Proxy filing

Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase

Oct 1, 2025, 9:00 AM EDT - 9 months ago

Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase

SCLX

Datavault AI Announces Closing of Initial Tranche Investment from Scilex Holding Company

Sep 26, 2025, 4:12 PM EDT - 9 months ago

Datavault AI Announces Closing of Initial Tranche Investment from Scilex Holding Company

DVLT SCLX

Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI

Sep 26, 2025, 3:57 PM EDT - 9 months ago

Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI

SCLX

Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI

Sep 25, 2025, 3:45 PM EDT - 9 months ago

Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI

SCLX

Scilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in Bitcoin

Sep 25, 2025, 6:00 AM EDT - 9 months ago

Scilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in Bitcoin

SCLX

Scilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management

Sep 24, 2025, 10:11 AM EDT - 9 months ago

Scilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management

SCLX

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) Announces Signing of a Securities Purchase Agreement with an Institutional Investor for the Purchase of $100 Million of shares of Semnur Common Stock in Exchange for $100 Million in Bitcoin

Sep 23, 2025, 11:12 AM EDT - 9 months ago

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) Announces Signing of a Securities Purchase Agreement with an Institutional Investor for the Purchase of $100 Million of shares of Semnur Common Stock in Exchange for $100 Million in Bitcoin

SCLX

Scilex Holding Company Announces Signing of a Securities Purchase Agreement with an Institutional Investor to Exchange $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held By Scilex Holding Company for $200 Million in Bitcoin

Sep 23, 2025, 10:00 AM EDT - 9 months ago

Scilex Holding Company Announces Signing of a Securities Purchase Agreement with an Institutional Investor to Exchange $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held By Scilex Holding Company for $200 Million in Bitcoin

SCLX

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025

Sep 23, 2025, 6:00 AM EDT - 9 months ago

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025

SCLX

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination

Sep 22, 2025, 3:49 PM EDT - 9 months ago

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination

SCLX

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali's Shareholders of the Previously Announced Business Combination

Sep 4, 2025, 9:00 AM EDT - 10 months ago

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali's Shareholders of the Previously Announced Business Combination

SCLX

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex's CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulatory Approval and Commercialization for the Treatment of Lumbosacral Radicular Pain (LRP)/Sciatica

Aug 21, 2025, 6:00 AM EDT - 10 months ago

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex's CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulatory Approval and Commercialization for the Treatment of Lumbosacral Radicular Pain (LRP)/Sciatica

SCLX

Scilex Holding Company Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Scilex Holding Company Quarterly report: Q2 2025

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

Aug 13, 2025, 6:00 AM EDT - 11 months ago

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

SCLX

Scilex Holding Company Registration statement: Registration filing

Aug 4, 2025, 8:00 AM EDT - 11 months ago

Scilex Holding Company Registration statement: Registration filing

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

Jun 23, 2025, 4:50 PM EDT - 1 year ago

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

SCLX

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

Jun 5, 2025, 12:05 PM EDT - 1 year ago

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

SCLX

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025, 9:00 AM EDT - 1 year ago

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

SCLX

Scilex Holding Company Proxy statement: Proxy filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Scilex Holding Company Proxy statement: Proxy filing

Scilex Holding Company Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Scilex Holding Company Quarterly report: Q1 2025

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025, 9:00 AM EDT - 1 year ago

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

SCLX

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

Apr 30, 2025, 1:46 PM EDT - 1 year ago

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

SCLX

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

Apr 22, 2025, 9:00 AM EDT - 1 year ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

SCLX

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

Apr 16, 2025, 2:12 PM EDT - 1 year ago

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

SCLX

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

Apr 15, 2025, 9:00 AM EDT - 1 year ago

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

SCLX

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Apr 11, 2025, 9:00 AM EDT - 1 year ago

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

SCLX

Scilex Holding Company Annual report: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Scilex Holding Company Annual report: Q4 2024

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

Mar 26, 2025, 8:24 PM EDT - 1 year ago

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

SCLX

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Mar 10, 2025, 9:00 AM EDT - 1 year ago

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

SCLX

Scilex Holding Company Proxy statement: Proxy filing

Feb 27, 2025, 7:00 AM EST - 1 year ago

Scilex Holding Company Proxy statement: Proxy filing

Scilex Holding Company Proxy statement: Proxy filing

Feb 26, 2025, 7:00 AM EST - 1 year ago

Scilex Holding Company Proxy statement: Proxy filing

Scilex Holding Company Proxy statement: Proxy filing

Feb 14, 2025, 7:00 AM EST - 1 year ago

Scilex Holding Company Proxy statement: Proxy filing

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Jan 31, 2025, 9:00 AM EST - 1 year ago

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

SCLX

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Jan 21, 2025, 11:49 AM EST - 1 year ago

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

SCLX

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Jan 21, 2025, 9:46 AM EST - 1 year ago

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

SCLX

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Jan 21, 2025, 9:00 AM EST - 1 year ago

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

SCLX

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Jan 21, 2025, 6:00 AM EST - 1 year ago

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

SCLX

Scilex Holding Company Quarterly report: Q3 2024

Jan 17, 2025, 7:00 AM EST - 1 year ago

Scilex Holding Company Quarterly report: Q3 2024

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Jan 16, 2025, 3:38 PM EST - 1 year ago

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

SCLX